Infection due to Staphylococcus aureus remains a major clinical problem even in the era of aggressive use of potent antibiotic agents (17, 18) . A number of bacterial products (e.g., toxins, extracellular enzymes) have been correlated with various staphylococcal diseases, but none appears to be related either to the occurrence of bacteremia or to the invasiveness of this organism (4, 18) . Capsular polysaccharides associated with many different bacteria (Streptococcus pneumoniae, Klebsiella pneumoniae, Haemophilus influenzae type b, Neisseria meningitidis, Escherichia coli, and group B Streptococcus agalactiae) (14) account, in part, for the invasiveness of these organisms. Although capsular polysaccharides have been demonstrated in several mucoid strains of S. aureus designated Smith (6, 19) , M (16) , T (20) , K93-M (5), 7007 (7), D (10) , and Mardi (9) , organisms with these capsular types are rarely isolated from infected patients (8) .
An S. aureus capsular polysaccharide typing classification has been developed (8) . In that study, clinical isolates were classified into eight distinct capsular types by using polyclonal, type-specific antisera. A recent clinical survey indicated that two S. aureus capsular types, type 5 and type 8, account for over 70% of S. aureus bacteremias (1) .
This report describes the production and characterization of monoclonal antibodies reactive with type 5 and type 8 strains of S. aureus.
MATERIALS AND METHODS
Bacteria. Bacteria were cultivated overnight at 37°C on Columbia agar supplemented with 1% NaCl under 5% CO2. Organisms were removed from the agar plates, washed in phosphate-buffered saline (PBS), and either heat killed at 70°C for 1 h or treated with 3% Formalin overnight at 4°C, and then they were washed with 0.3% Formalin in PBS.
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typing, preparation of type-specific rabbit antisera, and the source and identification of the prototype strains used have been described previously (8) . Isolates were typed originally by immunoelectrophoresis or immunodiffusion of culture extracts, or both. S. aureus strains possessing capsular types 1 (strain D), 2 (strain Smith), 4 (strain 7007), 6 (strain C), and 7 (strain 207) were described previously (8) . The various type 5, type 8, and nontypeable S. aureus clinical isolates used in this study are listed in Table 1 along with their associated phage and capsular types. Reynold (type 5) and Becker (type 8) are the prototype strains for their respective capsular types (8) . The remainder of the strains were S. aureus bacteremia isolates from the Veterans Administration Medical Center, Boston, Mass. S. aureus isolates were phage typed by the Staphylococcal Typing Laboratory, Bacterial Pathogens Branch, Centers for Disease Control, Atlanta, Ga., through the cooperation of P. B. Smith and G. Hancock. Production of type-specific anti-S. aureus monoclonal antibodies. BALB/c strain mice (Jackson Laboratory, Bar Harbor, Maine) were immunized three times with Formalinfixed S. aureus bacterial vaccines, with the last immunization given 3 days before fusion. Spleen cells derived from immune mice were fused with the mouse myeloma fusion partner, X63-Ag8.653 (11) at a 6:1 lymphocyte:myeloma ratio in polyethylene glycol (PEG 1000; J. T. Baker Chemical Co., Phillipsburg, N.J.) according to the method of Gefter et al. (3) . Cell suspensions were plated in 96-well microtiter trays, and hybrids were selected in medium containing hypoxanthine-aminopterin-thymidine by the method of Littlefield (12) . Hybridomas were cloned by limiting dilution.
Hybridoma cell culture supernatants were screened for anti-S. aureus antibody activity by bacterial agglutination. Immunoglobulin subclass determinations were performed by enzyme-linked immunosorbent assay (ELISA) with reagents Bacterial agglutination assays. Bacterial agglutination assays were performed in round-bottomed 96-well microtiter plates with suspensions of heat-killed, trypsinized organisms. Bacterial cell suspensions were diluted in PBS to an optical density of 1.0 at 550 nm, and 25 ,ul was mixed with 25 ,ul of hybridoma culture supernatants. The plates were incubated for 1 h at 37°C and then overnight at 4°C. The agglutination patterns were read the next day, and results were scored on a scale from 0 (the complete absence of agglutination) to 4+ (complete agglutination).
ELISA. The ELISA with whole bacteria was performed in 96-well polyvinyl chloride microtiter trays (Costar, Cambridge, Mass.). Formalin-fixed bacterial suspensions were diluted in PBS to an optical density of 1.0 and were incubated in the wells at room temperature overnight. The next day, the bacteria were pelleted by centrifugation, nonadherent bacteria were removed by being washed with PBS, and the wells were blocked with PBS containing 1% normal goat serum. Hybridoma culture supernatants (50 ,ul) were added to the wells and incubated for 3 h at room temperature. The wells were washed with PBS, and the monoclonal antibodies which bound to the solid phase were detected with horseradish peroxidase-conjugated anti-mouse immunoglobulin (New England Nuclear Corp., Boston, Mass. Type-specific, anti-S. aureus monoclonal antibodies were also assayed for reactivity in ELISA against Formalin-fixed whole organisms (Fig. 1) . The reactivity patterns were 0.001 17-4 . 0.002 17-5 . 0.008 17-6 . 0.006 17-7 . 0.007 17-8 . 0.006 17-10 . 0.002 17-11 . 0.001 17-12 . 0.010 17-13 . 0.004 17-14 . 0.004 17-17 . 0.010 17-18 . 0.009 17-20 . 0 0.400 18-10 . 0.560 18-11 . 0.486 18-12 . 0.658 a Avidin-coated polystyrene microtiter trays (96 wells) were incubated with biotin-derivatized, purified S. aureus type 8 capsular polysaccharide as described in the text.
b Determined by bacterial agglutination (Table 2 ) and whole bacteria ELISA (Fig. 1) .
c Hybridoma culture supernatants were added to type 8 capsular polysaccharide-coated wells and were incubated overnight at room temperature. Antibody binding was assessed with horseradish peroxidase-conjugated goat anti-mouse immunoglobulin in ELISA as described in the text. equivalent to those obtained by agglutination. Cell culture supernatants from fusion 17 reacted in ELISA with type 5 S. aureus strains. Monoclonal antibody 17-2 possessed marginal ELISA reactivity despite the fact that it had agglutinating reactivity. This might be the result of antibody 17-2 having a low affinity and being more likely to be washed off the microtiter plate during the ELISA. Low-affinity antibodies should not have this property in the agglutination assay, because no wash steps are involved. The anti-type 5 monoclonal antibodies did not react in ELISA with either type 8 or nontypeable S. aureus clinical isolates. In addition, the anti-type 5 antibodies did not react with S. epidermidis or with a variety of gram-negative controls (data not shown).
The nine anti-type 8 monoclonal antibodies derived from fusion 18 were also tested for activity in the ELISA (Fig. 1) Reactivity of type-specific anti-S. aureus monoclonal antibodies with purified capsular polysaccharides. Reactivity of type-specific, anti-S. aureus monoclonal antibodies was assessed further by using purified capsular polysaccharide in ELISA (Table 3 ). The monoclonal antibodies specific for type 8 S. aureus reacted strongly with type 8 capsular polysaccharide, giving ELISA optical density values ranging from 0.105 to 0.765. The antibodies were completely unreactive with purified teichoic acid derived from a nontypeable strain of S. aureus (data not shown). Monoclonal antibodies specific for type 5 S. aureus did not react with purified type 8 capsular polysaccharides in ELISA. DISCUSSION The serologic reactivities of the type-specific, anti-S. aureus monoclonal antibodies described in this report are concordant with those of previous studies, (1, 8) with polyclonal rabbit antisera. Nineteen different monoclonal antibodies derived from mice immunized with the prototype type 5 strain were reactive with each of four different clinical isolates of S. aureus possessing type 5 capsular polysaccharides. The antibodies did not react with types 1, 2, 6, 7, and 8 S. aureus, nontypeable S. aureus, S. epidermidis, or a variety of gram-negative organisms.
The serologic reactivities of the nine different anti-type 8 monoclonal antibodies were similarly concordant with data obtained by using polyclonal typing reagents. These antibodies reacted with five different S. aureus strains that possessed type 8 capsular polysaccharides. No reactivity was seen with types 1, 2, 4, 5, and 7 S. aureus, nontypeable S. aureus, S. epidermidis, or a variety of gram-negative organisms.
Several lines of evidence support the conclusion that the monoclonal antibodies described in this report are reactive with the type-specific capsular polysaccharides described by Karakawa and Vann (8) . First, both sets of type-specific monoclonal antibodies are reactive with heat-stable, trypsinresistant, bacterial cell surface antigens, as demonstrated by the agglutination assays (Table 2) . Second, the serologic reactivity and specificity of the monoclonal antibodies in both the agglutination assays (Table 2 ) and whole organism ELISA (Fig. 1) correlate with the capsular types assigned by using polyclonal typing reagents. Third, at least with regard to the monoclonal antibodies specific for type 8 strains of S. aureus, the antibodies react in ELISA with purified type 8 capsular polysaccharides (Table 3) . Thus far, we have been unable to show that any of the anti-type 5 monoclonal antibodies react with purified type 5 capsular polysaccharide antigen. The extraction or purification procedure, or both, may modify or destroy the epitopes to which the anti-type 5 antibodies are directed. We are currently investigating alternate methods of purification for the type 5 capsular polysaccharides.
The bacterial antigens considered in this and previous studies (1, 2, 8) are cell surface polysaccharides. Biochemically, they are acidic polymers containing uronic acids (2) . Functionally, these bacterial cell surface molecules mask cell wall antigens such as teichoic acid and peptidoglycan, as documented by agglutination studies (8) . In these characteristics, they are similar to previously well-defined capsular polysaccharides of other organisms such as S. pneumoniae and H. influenzae (14) . However, as has been stressed previously, the strains studied here do not appear grossly mucoid on routine in vitro culture (1) . Further studies are required to define the role of these polysaccharides in the pathogenesis of invasive staphylococcal infection and the potential for protection by type-specific antibody.
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described in this report will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease.
